产品中心
-
产品货号
产品名称
规格
销售价
会员价
货期
产地
订购
-
C106
Recombinant Human BID/BH3-interacting domain death agonist
10ug
640
576
现货
国产
-
C106
Recombinant Human BID/BH3-interacting domain death agonist
50ug
2000
1800
现货
国产
-
C106
Recombinant Human BID/BH3-interacting domain death agonist
500ug
12320
11088
现货
国产
-
C106
Recombinant Human BID/BH3-interacting domain death agonist
1mg
17600
15840
现货
国产
- 产品简介
- 使用说明
- 相关产品
- 参考文献
- 购买咨询
Catalog# C106 Source E.coli Description Recombinant Human BH3-Interacting Domain Death Agonist/BID is produced with our E. coli expression system. The target protein is expressed with sequence (Met1-Asp195) of Human BID protein. Names BH3-Interacting Domain Death Agonist, p22 BID, BID Accession # P55957 Formulation Supplied as a 0.2 μm filtered solution of 20mM PB, 100mM KCl, pH 7.4 Shipping The product is shipped on dry ice/ice packs. Storage Store at < -20°C, stable for 6 months after receipt.
Please minimize freeze-thaw cycles.Purity Greater than 95% as determined by SEC-HPLC and reducing SDS-PAGE. Endotoxin Less than 0.1 ng/μg (1 IEU/μg). Amino Acid Sequence MDCEVNNGSSLRDECITNLLVFGFLQSCSDNSFRRELDALGHELPVLAPQWEGYDELQTDGNRSS HSRLGRIEADSESQEDIIRNIARHLAQVGDSMDRSIPPGLVNGLALQLRNTSRSEEDRNRDLATA LEQLLQAYPRDMEKEKTMLVLALLLAKKVASHTPSLLRDVFHTTVNFINQNLRTYVRSLARNGMDBackground BH3-Interacting Domain Death Agonist (BID) is a member of the Bcl-2 protein family which regulates outer mitochondrial membrane permeability. BID is a pro-apoptotic member that causes cytochrome c to be released from the mitochondria intermembrane space into the cytosol. Interaction of Bid with Bak causes altered mitochondrial membrane permeability. BID contains only the BH3 domain, which is required for its interaction with the Bcl-2 family proteins and for its pro-death activity. BID is susceptible to proteolytic cleavage by caspases, calpains, Granzyme B and cathepsins. It is an integrating key regulator of the intrinsic death pathway that amplifies caspase-dependent and caspase-independent execution of neuronal apoptosis. Therefore pharmacological inhibition of BID provides a promising therapeutic strategy in neurological diseases where programmed cell death is prominent, and also offer a new strategy for the treatment of acute renal failure associated with ischemia-reperfusion. BID receives direct inputs from a key regulator of the cell cycle arrest/DNA repair machinery (ATM), and therefore is an excellent candidate to coordinate genotoxic stress responses and apoptotic cell death. BID is a novel pro-apoptosis Bcl-2 family protein that is activated by caspase 8 in response to Fas/TNF-R1 death receptor signals. Deletion of BID inhibits carcinogenesis in the liver, although this genetic alteration promotes tumorigenesis in the myeloid cells. This is likely related to the function of BID to promote cell cycle progression into S phase. BID could be also involved in the maintenance of genomic stability by engaging at mitosis checkpoint.